Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure

Circulation

Volumn 100, Issue 23, 1999, Pages 2312-2318

  Packer, Milton ^a   Poole Wilson, Philip A ^a   Armstrong, Paul W ^b   Cleland, John G F ^f   Horowitz, John D ^f   Massie, Barry M ^c   Rydén, Lars ^d   Thygesen, Kristian ^f   Uretsky, Barry F ^e  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f Columbia Univ Coll Phys Surgs ^*

Author keywords

Drugs; Heart failure; Morbidity; Mortality; Trials

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033534085     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.23.2312     Document Type: Article

References (18)

1. ACC/AHA Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure. Circulation. 1995;92: 2764-2784.
2. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J. 1997;18:736-753.
3. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77:832-838.
4. Smith NL, Psaty BM, Pitt B, Garg R, Gottdiener JS, Heckbert SR. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med. 1998;158:1074-1080.
5. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 333:1670-1676.
6. Ader R, Chatterjee K, Ports T, Brundage B, Hiramtsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by oral angiotensin-converting enzyme inhibitor. Circulation. 1980;61:931-937.
7. DiCarlo L, Chatterjee K, Parmley WW, Swedberg K, Atherton B, Curran D, Cucci M. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. J Am Coll Cardiol. 1983;2:865-871.
8. Uretsky BF, Shaver JA, Liang C-S, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE. Modulation of hemodynamic effects with converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observation on long-term clinical, functional and biochemical responses. Am Heart J. 1988;116:480-488.
9. Riegger GAJ. Effects of quinapril on exercise tolerance testing in patients with mild to moderate congestive heart failure. Eur Heart J. 1991;12: 705-711.
10. Pacher R, Stanek B, Globits S, Berger R, Hussman M, Wutte M, Frey B, Schuller M, Hartter E, Ogris E. Effects of two different enalapril dosages on clinical, haemodynamic and neurohormonal response of patients with severe congestive heart failure. Eur Heart J. 1996;17:1223-1232.
11. Cleland JGF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Rydén L. Baseline clinical characteristics of patients recruited into the Assessment of Treatment with Lisinopril and Survival study. Eur J Heart Failure. 1999;1:73-79.
12. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316:1429-1435.
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:292-302.
14. Zannad F, van den Broek SA, Bory M. Comparison of treatment with lisinopril versus enalapril for congestive heart failure. Am J Cardiol. 1992;70:78C-83C.
15. Lan KKG, DeMets DL. Discrete sequential boundaries of clinical trials. Biometrika. 1983;70:659-663.
16. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
17. Wollert KC, Studer R, von Bulow B, Drexler H. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation. 1994;90:2457-2467.
18. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J. 1998;19: 481-489.